Stable liquid vigabatrin pharmaceutical composition for oral dosage
US11738020B2 · kind B2 · utility
0Cited by
0References
11Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Aug 16, 2019 |
| Grant date | Aug 29, 2023 |
| Priority date | — |
| Expiry date | Jun 4, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.